128 related articles for article (PubMed ID: 31998734)
21. Improved impurity fingerprinting of heparin by high resolution (1)H NMR spectroscopy.
Bigler P; Brenneisen R
J Pharm Biomed Anal; 2009 May; 49(4):1060-4. PubMed ID: 19211212
[TBL] [Abstract][Full Text] [Related]
22. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
[TBL] [Abstract][Full Text] [Related]
23. Detection of high-charge density polyanion contaminants in biomedical heparin preparations using potentiometric polyanion sensors.
Wang L; Buchanan S; Meyerhoff ME
Anal Chem; 2008 Dec; 80(24):9845-7. PubMed ID: 19007240
[TBL] [Abstract][Full Text] [Related]
24. Determination of impurities in heparin by capillary electrophoresis using high molarity phosphate buffers.
Wielgos T; Havel K; Ivanova N; Weinberger R
J Pharm Biomed Anal; 2009 Feb; 49(2):319-26. PubMed ID: 19155153
[TBL] [Abstract][Full Text] [Related]
25. Interactions of oversulfated chondroitin sulfate (OSCS) from different sources with unfractionated heparin.
Gray A; Litinas E; Jeske W; Fareed J; Hoppensteadt D
Clin Appl Thromb Hemost; 2012; 18(2):166-73. PubMed ID: 22311630
[TBL] [Abstract][Full Text] [Related]
26. Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for detection of heparin falsifications and protein in heparins.
Alban S; Lühn S; Schiemann S
Anal Bioanal Chem; 2011 Jan; 399(2):681-90. PubMed ID: 20953779
[TBL] [Abstract][Full Text] [Related]
27. Highly sensitive potentiometric strip test for detecting high charge density impurities in heparin.
Kang Y; Gwon K; Shin JH; Nam H; Meyerhoff ME; Cha GS
Anal Chem; 2011 May; 83(10):3957-62. PubMed ID: 21500820
[TBL] [Abstract][Full Text] [Related]
28. Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market.
Beyer T; Matz M; Brinz D; Rädler O; Wolf B; Norwig J; Baumann K; Alban S; Holzgrabe U
Eur J Pharm Sci; 2010 Jul; 40(4):297-304. PubMed ID: 20399266
[TBL] [Abstract][Full Text] [Related]
29. Agarose-gel electrophoresis for the quality assurance and purity of heparin formulations.
Volpi N; Buzzega D
J Pharm Biomed Anal; 2012; 67-68():144-7. PubMed ID: 22534509
[TBL] [Abstract][Full Text] [Related]
30. New developments in quantitative polymerase chain reaction applied to control the quality of heparins.
Auguste C; Dereux S; Martinez C; Anger P
Anal Bioanal Chem; 2011 Jan; 399(2):747-55. PubMed ID: 20931175
[TBL] [Abstract][Full Text] [Related]
31. An assessment of polydispersed species in unfractionated and low molecular weight heparins by diffusion ordered nuclear magnetic resonance spectroscopy method.
Bednarek E; Sitkowski J; Bocian W; Mulloy B; Kozerski L
J Pharm Biomed Anal; 2010 Nov; 53(3):302-8. PubMed ID: 20417048
[TBL] [Abstract][Full Text] [Related]
32. Characterization of heparin impurities with HPLC-NMR using weak anion exchange chromatography.
Limtiaco JF; Jones CJ; Larive CK
Anal Chem; 2009 Dec; 81(24):10116-23. PubMed ID: 19911825
[TBL] [Abstract][Full Text] [Related]
33. Antithrombin activity and disaccharide composition of dermatan sulfate from different bovine tissues.
Osborne SA; Daniel RA; Desilva K; Seymour RB
Glycobiology; 2008 Mar; 18(3):225-34. PubMed ID: 18156656
[TBL] [Abstract][Full Text] [Related]
34. Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects.
Tovar AM; Capillé NV; Santos GR; Vairo BC; Oliveira SN; Fonseca RJ; Mourão PA
Thromb Haemost; 2012 May; 107(5):903-15. PubMed ID: 22437650
[TBL] [Abstract][Full Text] [Related]
35. Preparation and Application of Nanosensor in Safeguarding Heparin Supply Chain.
Bi Y; Le KD; Ramamoorthy G; Kuberan B
SLAS Technol; 2020 Aug; 25(4):397-403. PubMed ID: 32589074
[TBL] [Abstract][Full Text] [Related]
36. Comparison of established and novel purity tests for the quality control of heparin by means of a set of 177 heparin samples.
Alban S; Lühn S; Schiemann S; Beyer T; Norwig J; Schilling C; Rädler O; Wolf B; Matz M; Baumann K; Holzgrabe U
Anal Bioanal Chem; 2011 Jan; 399(2):605-20. PubMed ID: 20824424
[TBL] [Abstract][Full Text] [Related]
37. Levothyroxine sodium revisited: A wholistic structural elucidation approach of new impurities via HPLC-HRMS/MS, on-line H/D exchange, NMR spectroscopy and chemical synthesis.
Ruggenthaler M; Grass J; Schuh W; Huber CG; Reischl RJ
J Pharm Biomed Anal; 2017 Feb; 135():140-152. PubMed ID: 28024262
[TBL] [Abstract][Full Text] [Related]
38. Determination of galactosamine impurities in heparin samples by multivariate regression analysis of their (1)H NMR spectra.
Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
Anal Bioanal Chem; 2011 Jan; 399(2):635-49. PubMed ID: 20953772
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin.
Douaisi M; Paskaleva EE; Fu L; Grover N; McManaman CL; Varghese S; Brodfuehrer PR; Gibson JM; de Joode I; Xia K; Brier MI; Simmons TJ; Datta P; Zhang F; Onishi A; Hirakane M; Mori D; Linhardt RJ; Dordick JS
Proc Natl Acad Sci U S A; 2024 Apr; 121(14):e2315586121. PubMed ID: 38498726
[TBL] [Abstract][Full Text] [Related]
40. The use of SAX-HPLC-CD as a heparin screening strategy.
Chmielewski AJ; Stanley FE; Stalcup AM
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Sep; 879(25):2619-23. PubMed ID: 21831728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
